Delving into the Latest Updates on Aluminum hydroxide/Magnesium Hydroxide with Synapse

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Start Date09 Nov 2023

Sponsor / Collaborator

Stony Brook University

NCT01930045

/ CompletedPhase 1

A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen

This study evaluated the effect of single doses of a magnesium/aluminum antacid (MAALOX) given 4 and 6 hours before or after administration of raltegravir, on the pharmacokinetics of raltegravir in human immunodeficiency virus (HIV)-infected participants. The study consisted of Part 1 (Periods 1, 2, and 3) and Part 2 (Periods 4 and 5), with each study period separated by a washout period of at least 2 days; Part 1 was separated from Part 2 by a Pause. Each study period had a duration of ≥2 days, and paused for evaluation of Part 1 pharmacokinetics results before continuing to Part 2. The same participants participated in Parts 1 and 2. The primary hypothesis tested (in Part 1) was that raltegravir plasma concentration 12 hours after administration (C 12 hrs) would not differ significantly from raltegravir C 12 hrs when antacid is administered 4 hours before or 4 hours after raltegravir.

Start Date01 Oct 2013

Sponsor / Collaborator

Merck Sharp & Dohme Corp.

NCT01281501

/ CompletedPhase 4IIT

A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain

The purpose of this study is to evaluate the immediate synergistic effect on the relief of severe acid-related dyspeptic pain by adding intravenous pantoprazole to the combination of oral antacid and antispasmodic agent (the conventional treatment).

Start Date01 Jan 2011

Sponsor / Collaborator

University of Chulalongkorn

100 Clinical Results associated with Aluminum hydroxide/Magnesium Hydroxide

Login to view more data

100 Translational Medicine associated with Aluminum hydroxide/Magnesium Hydroxide

Login to view more data

100 Patents (Medical) associated with Aluminum hydroxide/Magnesium Hydroxide

Login to view more data

187

Literatures (Medical) associated with Aluminum hydroxide/Magnesium Hydroxide

27 Jan 2025·Optics Express

Point spread function measurements for underwater imaging: an analysis of wavelength-specific behavior for image deconvolution

Article

Author: Zielinski, Oliver ; Schmidt, Jendrik ; Peters, Enno ; Stephan, Maurice

Underwater optical imaging, especially in coastal waters, suffers from reduced spatial resolution and contrast by forward scattered light. With the increased number of hyper- and multi-spectral imaging applications, the effect of the point spread function (PSF) at different spectral bands becomes increasingly more relevant. In this work, extensive laboratory measurements of the PSF at 450, 500, 550, 600 and 650 nm in different turbidity have been carried out. Measurements were performed in deionized water with added scattering agent Maalox and in selected natural waters. The experimental setup and measurement routine, including a HDR camera calibration allowing PSF measurements at more than 6 orders of magnitude, is described in detail. Measured PSFs are compared and discussed in terms of wavelength-specific slope behavior, showing significant shape differences between color channels with increasing Maalox concentration. Image deconvolutions of a test target with correct and wrong color PSF indicate the relevance of wavelength-specific PSF consideration, especially in correcting channels of longer wavelengths. The results also indicate, that PSFs derived from models that are based on single wavelength PSF measurements can be used to effectively restore images at different wavelength when acquired over long scattering ranges and being scaled properly.

01 Jul 2022·European Journal of Drug Metabolism and Pharmacokinetics

Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers

Article

Author: Nagelschmitz, Johannes ; Loewen, Stephanie ; Heinig, Roland

BACKGROUND AND OBJECTIVESFinerenone is a nonsteroidal mineralocorticoid receptor antagonist that reduces the risk of adverse kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes mellitus. Clinical phase I studies with finerenone were carried out to assess its pharmacokinetics and the influence of common covariables on its absorption after oral administration.METHODSThree crossover studies in healthy male volunteers with single-dose administration of finerenone investigated the dose linearity of a film-coated tablet (1.25-10 mg [n = 24] and 10-20 mg [n = 18]), the effect of food on the 20 mg tablet (n = 18), and the effects of the proton-pump inhibitor omeprazole (4 days pre-treatment and co-administration 2 h before finerenone) and an aluminum/magnesium hydroxide-containing antacid (10 mL [Maalox^®] 70 mVal, simultaneous intake) on the 10 mg tablet (n = 10 and n = 11, respectively).RESULTSFinerenone was rapidly absorbed (time to reach maximum plasma concentration [t_max] was 0.50-0.75 h). Area under the curve from zero to infinity (AUC_∞) and the maximum concentration (C_max) increased in proportion to dose in the range investigated in clinical phase II and phase III studies (1.25-20 mg), with point estimates for the ratio of dose-normalized AUC_∞ and C_max (20 mg/10 mg, approved therapeutic doses) of 0.9943 and 0.9301. After the administration of finerenone 20 mg with a high-fat, high-calorie meal, AUC_∞ increased (+ 21%), C_max decreased (-19%), and t_max was prolonged (2.47 vs. 0.75 h) when compared with the fasting state. Omeprazole had no effect on finerenone AUC_∞ and C_max. Maalox had no effect on finerenone AUC_∞ and led to a non-clinically-relevant decrease in C_max (-19%).CONCLUSIONSThe pharmacokinetics of the finerenone film-coated tablet were linear. High-fat, high-calorie food had no clinically relevant effect on the pharmacokinetics of finerenone. In addition, pH-modifying comedications were not found to alter the pharmacokinetics of finerenone and were deemed safe for co-administration.

01 May 2019·Clinical Pharmacology in Drug Development

Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open‐Label Randomized Crossover Study

Article

Author: Ren, Song ; Boulton, David W.

AbstractSaxagliptin is an orally administered, highly potent, and selective dipeptidyl peptidase‐4 inhibitor for the management of type 2 diabetes mellitus. This study was conducted to determine the effect of magnesium and aluminum hydroxides plus simethicone, famotidine, and omeprazole on the pharmacokinetics of saxagliptin and its active metabolite, 5‐hydroxy saxagliptin. This was an open‐label, randomized, 5‐treatment, 5‐period, 3‐way crossover study in 15 healthy subjects. Mean Cmax of saxagliptin was 26% lower, but AUC was almost unchanged when saxagliptin was coadministered with Maalox Max. Mean Cmax was 14% higher, but AUC was almost unchanged when saxagliptin was coadministered with famotidine. Changes in pharmacokinetics of 5‐hydroxy saxagliptin generally paralleled the changes in saxagliptin. These pharmacokinetic changes were unlikely to be clinically meaningful. Coadministration of omeprazole did not affect saxagliptin Cmax or AUC. Saxagliptin in combination with these medicines resulted in no unexpected safety or tolerability findings in these healthy subjects. No dose adjustment of saxagliptin or separation in the time of saxagliptin dosing is necessary with medicines that raise gastric pH when coadministered with saxagliptin.

100 Deals associated with Aluminum hydroxide/Magnesium Hydroxide

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Duodenal Ulcer	Japan	Sanofi KK	03 Mar 1992
Gastritis	Japan	Sanofi KK	03 Mar 1992
Stomach Ulcer	Japan	Sanofi KK	03 Mar 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumonia, Pneumococcal	Phase 2	United Kingdom	Genocea Biosciences, Inc.	30 Sep 2014
Malaria	Phase 2	Netherlands	Institut Pasteur	31 Oct 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00444275 (MAESTRO, CTgov)	Phase 4	Gastroesophageal Reflux	3,029	esomeprazole (Nexium®) (Esomeprazole 20 mg Once Daily (Maintenance Phase))	mktuqtxoab(kwttiytbxo) = yvvhbpyhcp lzjzuiclnr (qdnszsmnej, jcsddrksje - rpgapgthwr) View more	-	11 Dec 2012
				esomeprazole (Nexium®) (Esomeprazole 20 mg on Demand (Maintenance Phase))	mktuqtxoab(kwttiytbxo) = vugnoguyce lzjzuiclnr (qdnszsmnej, dnqciobzbt - pyxrhmgguc) View more
NCT01281501 (CTgov)	Phase 4	Dyspepsia \| Acute Pain	87	Hyoscine butylbromide+Oral antacid+Normal Saline (Conventional)	vrqutgbeom(cfvycpooeg) = obcnnmhozu aerwonsfeh (jdjqadkywt, tsapcmhqmc - gglvcvmygr) View more	-	27 Jul 2012
				Hyoscine butylbromide+Oral antacid+Pantoprazole (Pantoprazole)	vrqutgbeom(cfvycpooeg) = ltohsbooei aerwonsfeh (jdjqadkywt, ksvtobibfu - rriiewltoc) View more